NEW YORK – Antibody analysis firm Serimmune said on Friday that it has entered an agreement with biotech company Atreca around development of therapeutic antibodies for cancer.
Under the agreement, Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
The SERA platform uses a combination of bacterial display peptide libraries, next-generation sequencing, and machine learning to identify antigens involved in antibody response.
"We are excited that Atreca has chosen to collaborate with Serimmune to leverage the strengths of our proprietary platform for identifying the specific antigenic epitopes of antibody response," Serimmune CEO Noah Nasser said in a statement. "Atreca's antibody discovery platform provides a wealth of therapeutic candidates, and we look forward to providing valuable target information to help them select and advance those candidates."
Financial and other terms of the agreement were not disclosed.